Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
The acquisition complements and strengthens Merck’s cardiovascular pipeline
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Subscribe To Our Newsletter & Stay Updated
